Sickle Cell Disease Infographics

Sickle Cell Disease (SCD) is a genetic blood disorder caused by a mutation in the hemoglobin gene, leading to the production of abnormal hemoglobin S. This condition results in distorted, rigid, sickle-shaped red blood cells that impair blood flow and oxygen delivery throughout the body. SCD manifests through chronic pain episodes, anemia, infections, organ damage, and other severe complications. Risk factors include genetic inheritance, with a higher prevalence among individuals of African, Mediterranean, Middle Eastern, and Indian ancestry. Effective management focuses on symptom control, prevention of complications, and improving quality of life through innovative therapies and supportive care.

Sickle Cell Disease Epidemiological Segmentation

The Epidemiological Segmentation of Sickle Cell Disease in the 6MM from 2020 to 2034 includes:

• Total Prevalent Cases
• Total Diagnosed Prevalent Cases
• Type-specific Cases
• Treated Cases

Sickle Cell Disease Epidemiology

• In 2023, the total prevalent cases of Sickle Cell Disease in the 6MM were approximately 161K.
• The US accounted for 65% of the total prevalent cases, highlighting its significant disease burden.
• Within the US, the 18–44 years age group had the highest number of cases, reflecting the disease's substantial impact on young, economically active individuals.

Sickle Cell Disease Market

The total Sickle Cell Disease (SCD) market size in the 6MM was valued at approximately USD 650 million in 2023.

Sickle Cell Disease Market Drivers

• The rise of innovative therapies, including gene editing and disease-modifying treatments, has revolutionized the SCD treatment landscape, offering hope for long-term solutions.
• Increasing awareness and early diagnosis, coupled with government support and patient advocacy efforts, have driven market growth and improved patient access to care.

Sickle Cell Disease Market Barriers

• High costs of advanced therapies and limited access in low-income regions remain significant barriers to widespread adoption and equitable care.
• Complexities in clinical trial design and regulatory hurdles for new treatments can delay the availability of innovative therapies.

Sickle Cell Disease Emerging Drugs

• Ndec
• Mitapivat
• Inclacumab
• Reni-cel

And others

Sickle Cell Disease Key Players

• Global Blood Therapeutics
• Pfizer
• Agios Pharmaceuticals
• Editas Medicine
• Forma Therapeutics
• Novo Nordisk
• Bausch Health
• Bluebird Bio

And others